J Korean Assoc Oral Maxillofac Surg.  2019 Apr;45(2):76-82. 10.5125/jkaoms.2019.45.2.76.

Is treatment with platelet-rich fibrin better than zinc oxide eugenol in cases of established dry socket for controlling pain, reducing inflammation, and improving wound healing?

• Paul S
• Choudhury
• Kumari N
• Rastogi S
• Sharma A
• Singh V
• Laskar S
• Dubey T

• KMID: 2467150
• DOI: http://doi.org/10.5125/jkaoms.2019.45.2.76

Abstract

OBJECTIVES
To appraise the effectiveness of platelet-rich fibrin (PRF) in the management of established dry socket in terms of pain, inflammation, and wound healing.
MATERIALS AND METHODS
Two hundred patients with established alveolar osteitis were studied to determine the efficacy of PRF and zinc oxide eugenol (ZOE) for pain control, inflammation reduction, and wound healing. Patients were randomly allocated to Group A (PRF) or Group B (ZOE). Patients were examined on the 1st, 3rd, 7th, and 14th postoperative day and evaluated for pain using visual analogue scale scores, inflammation with a gingival index score, and wound healing through a determination of the number of bony walls exposed.
RESULTS
Group A showed better results in terms of pain remission, control of inflammation, and wound healing compared to Group B. Results between groups were statistically significant (P<0.05).
CONCLUSION
PRF is a better alternative than ZOE for the effective management of alveolar osteitis.

Keyword

Dry socket; Pain; Platelet-rich fibrin; Wound healing

MeSH Terms

Dry Socket*
Eugenol*
Fibrin*
Humans
Inflammation*
Periodontal Index
Wound Healing*
Wounds and Injuries*
Zinc Oxide*
Zinc*
Eugenol
Fibrin
Zinc
Zinc Oxide

Figure

• 

  Fig. 1 Flow diagram for patient recruitment and selection. (PRF: platelet-rich fibrin, ZOE: zinc oxide eugenol)

• 

  Fig. 2 Visual analogue scale (VAS) for pain at 1st, 3rd, 7th, and 14th day. Values are presented as mean. (Group A: platelet-rich fibrin, Group B: zinc oxide eugenol)

• 

  Fig. 3 Presence or absence of inflammation on 1st, 3rd, 7th, and 14th day. Values are presented as mean. (Group A: platelet-rich fibrin, Group B: zinc oxide eugenol)

• 

  Fig. 4 Assessment of bone healing through number of exposed walls on 1st, 3rd, 7th, and 14th day. Values are presented as mean. (Group A: platelet-rich fibrin, Group B: zinc oxide eugenol)

Reference

1. Bowe DC, Rogers S, Stassen LF. The management of dry socket/alveolar osteitis. J Ir Dent Assoc. 2011; 57:305–310. PMID: 22338284.

2. Crawford JY. Dry socket. Dent Cosms. 1896; 38:929–931.

3. Metin M, Tek M, Sener I. Comparison of two chlorhexidine rinse protocols on the incidence of alveolar osteitis following the surgical removal of impacted third molars. J Contemp Dent Pract. 2006; 7:79–86.

4. Bloomer CR. Alveolar osteitis prevention by immediate placement of medicated packing. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000; 90:282–284. PMID: 10982947.

5. Blum IR. Contemporary views on dry socket (alveolar osteitis): a clinical appraisal of standardization, aetiopathogenesis and management: a critical review. Int J Oral Maxillofac Surg. 2002; 31:309–317. PMID: 12190139.

6. Birn H. Etiology and pathogenesis of fibrinolytic alveolitis (“dry socket”). Int J Oral Surg. 1973; 2:211–263.

7. Tarakji B, Saleh LA, Umair A, Azzeghaiby SN, Hanouneh S. Systemic review of dry socket: aetiology, treatment, and prevention. J Clin Diagn Res. 2015; 9:ZE10–ZE13.

8. Fernandes GJ, Hatton MN. Prevention of alveolar osteitis. A case report and review of literature. N Y State Dent J. 2016; 82:21–25.

9. Kolokythas A, Olech E, Miloro M. Alveolar osteitis: a comprehensive review of concepts and controversies. Int J Dent. 2010; 2010:249073. PMID: 20652078.

10. Fridrich KL, Olson RA. Alveolar osteitis following surgical removal of mandibular third molars. Anesth Prog. 1990; 37:32–41. PMID: 2077984.

11. Wates E, Ria B. The prevention and management of dry socket: do antibiotics have a role to play? Prim Dent J. 2015; 4:42–43.

12. Hedström L, Sjögren P. Effect estimates and methodological quality of randomized controlled trials about prevention of alveolar osteitis following tooth extraction: a systematic review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007; 103:8–15. PMID: 17178488.

13. Nitzan DW. On the genesis of “dry socket”. J Oral Maxillofac Surg. 1983; 41:706–710. PMID: 6579255.

14. Xu JL, Sun L, Liu C, Sun ZH, Min X, Xia R. Effect of oral contraceptive use on the incidence of dry socket in females following impacted mandibular third molar extraction: a meta-analysis. Int J Oral Maxillofac Surg. 2015; 44:1160–1165. PMID: 26116066.

15. Jesudasan JS, Wahab PU, Sekhar MR. Effectiveness of 0.2% chlorhexidine gel and a eugenol-based paste on postoperative alveolar osteitis in patients having third molars extracted: a randomised controlled clinical trial. Br J Oral Maxillofac Surg. 2015; 53:826–830. PMID: 26188932.

16. Khiyavi RK, Barghi VG, Yazdani J, Ghavimi MA, Khiyavi SG, Ebrahimi H. Effect of Biotene mouth wash on prevention of alveolar osteitis after extraction of permanent mandibular first molar teeth. Elixir Hum Physiol. 2012; 47:8672–8674.

17. Ross R, Glomset J, Kariya B, Harker L. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci U S A. 1974; 71:1207–1210. PMID: 4208546.

18. Choukroun J, Diss A, Simonpieri A, Girard MO, Schoeffler C, Dohan SL, et al. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part V: histologic evaluations of PRF effects on bone allograft maturation in sinus lift. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006; 101:299–303. PMID: 16504861.

19. Haraji A, Lassemi E, Motamedi MH, Alavi M, Adibnejad S. Effect of plasma rich in growth factors on alveolar osteitis. Natl J Maxillofac Surg. 2012; 3:38–41. PMID: 23251056.

20. Pal US, Singh BP, Verma V. Comparative evaluation of zinc oxide eugenol versus gelatin sponge soaked in plasma rich in growth factor in the treatment of dry socket: an initial study. Contemp Clin Dent. 2013; 4:37–41. PMID: 23853450.

21. Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJ, Mouhyi J, et al. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part I: technological concepts and evolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006; 101:e37–e44. PMID: 16504849.

22. Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJ, Mouhyi J, et al. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part II: platelet-related biologic features. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006; 101:e45–e50. PMID: 16504850.

23. Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJ, Mouhyi J, et al. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part III: leucocyte activation: a new feature for platelet concentrates? Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006; 101:e51–e55. PMID: 16504851.

24. Eshghpour M, Rezaei NM, Nejat A. Effect of menstrual cycle on frequency of alveolar osteitis in women undergoing surgical removal of mandibular third molar: a single-blind randomized clinical trial. J Oral Maxillofac Surg. 2013; 71:1484–1489. PMID: 23866782.

25. Ogundipe OK, Ugboko VI, Owotade FJ. Can autologous platelet-rich plasma gel enhance healing after surgical extraction of mandibular third molars? J Oral Maxillofac Surg. 2011; 69:2305–2310. PMID: 21550158.